galactosamine has been researched along with Disbacteriosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, K; Li, L; Li, Q; Li, S; Lou, Y; Si, G; Tang, R; Wo, W; Xia, J; Zha, H | 1 |
| Bian, X; Jiang, H; Jiang, X; Li, L; Li, Y; Lu, Y; Lv, L; Shen, J; Wang, K; Wang, Q; Wu, J; Wu, W; Xie, J; Yan, R; Yang, L; Ye, J | 1 |
| Chen, L; Chen, X; Jiang, H; Li, L; Lv, L; Wang, K; Wang, Q; Yan, R | 1 |
| Bian, X; Fang, D; Jiang, H; Jiang, X; Li, L; Li, Y; Lv, L; Peng, C; Shi, D; Wang, Q; Wu, J; Wu, W; Yan, R; Yang, L; Ye, J | 1 |
4 other study(ies) available for galactosamine and Disbacteriosis
| Article | Year |
|---|---|
Characteristics of the intestinal bacterial microbiota profiles in Bifidobacterium pseudocatenulatum LI09 pre-treated rats with D-galactosamine-induced liver injury.
Topics: Animals; Bacteria; Bifidobacterium pseudocatenulatum; Chemical and Drug Induced Liver Injury, Chronic; Dysbiosis; Galactosamine; Gastrointestinal Microbiome; Liver; Microbiota; Rats | 2022 |
Bifidobacterium longum R0175 Protects Rats against d-Galactosamine-Induced Acute Liver Failure.
Topics: Animals; Aspartate Aminotransferases; Bifidobacterium longum; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Chemokines; Cytokines; Dysbiosis; Galactosamine; Gastrointestinal Microbiome; Male; Probiotics; Rats; Rats, Sprague-Dawley | 2020 |
Lactobacillus reuteri DSM 17938 alleviates d-galactosamine-induced liver failure in rats.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Cytokines; Disease Models, Animal; Dysbiosis; Galactosamine; Gastrointestinal Microbiome; Ileum; Inflammation Mediators; Limosilactobacillus reuteri; Liver; Liver Failure; Male; Metabolome; Peroxisome Proliferator-Activated Receptors; Probiotics; Rats, Sprague-Dawley; Signal Transduction; Transcriptome | 2021 |
Bifidobacterium adolescentis CGMCC 15058 alleviates liver injury, enhances the intestinal barrier and modifies the gut microbiota in D-galactosamine-treated rats.
Topics: Acute-Phase Proteins; Animals; Bifidobacterium adolescentis; Carrier Proteins; Chemical and Drug Induced Liver Injury; Cytokines; Dysbiosis; Feces; Galactosamine; Gastrointestinal Microbiome; Humans; Intestines; Liver; Male; Membrane Glycoproteins; Rats, Sprague-Dawley | 2019 |